vs
QuidelOrtho Corp(QDEL)与Ryman Hospitality Properties, Inc.(RHP)财务数据对比。点击上方公司名可切换其他公司
Ryman Hospitality Properties, Inc.的季度营收约是QuidelOrtho Corp的1.1倍($737.8M vs $699.9M),Ryman Hospitality Properties, Inc.净利率更高(10.1% vs -104.7%,领先114.8%),Ryman Hospitality Properties, Inc.同比增速更快(13.9% vs -3.7%),Ryman Hospitality Properties, Inc.自由现金流更多($58.5M vs $-94.7M),过去两年Ryman Hospitality Properties, Inc.的营收复合增速更高(18.2% vs -2.9%)
奎德尔奥索公司是美国的诊断医疗产品制造商,旗下产品面向全球市场销售,深耕体外诊断领域,为医疗机构及相关用户提供专业的检测解决方案,助力全球医疗健康服务效率提升。
莱曼酒店地产是一家主营酒店、度假村、娱乐及媒体业务的企业,得名于旗下位于田纳西州纳什维尔的国家历史地标莱曼礼堂。公司历史可追溯至曾为俄克拉荷马出版公司子公司时期,1983年收购WSM公司后奠定现代业务基础,同时将知名演出IP大奥普里等核心资产纳入麾下。
QDEL vs RHP — 直观对比
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | ||
|---|---|---|
| 营收 | $699.9M | $737.8M |
| 净利润 | $-733.0M | $74.5M |
| 毛利率 | — | 41.4% |
| 营业利润率 | -100.7% | 19.4% |
| 净利率 | -104.7% | 10.1% |
| 营收同比 | -3.7% | 13.9% |
| 净利润同比 | -3583.4% | 3.0% |
| 每股收益(稀释后) | $-10.78 | $1.12 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比,按日历期对齐,财年错位的公司也能正确匹配
| Q4 25 | — | $737.8M | ||
| Q3 25 | $699.9M | $592.5M | ||
| Q2 25 | $613.9M | $659.5M | ||
| Q1 25 | $692.8M | $587.3M | ||
| Q4 24 | $707.8M | $647.6M | ||
| Q3 24 | $727.1M | $550.0M | ||
| Q2 24 | $637.0M | $613.3M | ||
| Q1 24 | $711.0M | $528.3M |
| Q4 25 | — | $74.5M | ||
| Q3 25 | $-733.0M | $34.9M | ||
| Q2 25 | $-255.4M | $71.8M | ||
| Q1 25 | $-12.7M | $63.0M | ||
| Q4 24 | $-178.4M | $72.3M | ||
| Q3 24 | $-19.9M | $59.0M | ||
| Q2 24 | $-147.7M | $100.8M | ||
| Q1 24 | $-1.7B | $42.8M |
| Q4 25 | — | 41.4% | ||
| Q3 25 | — | 40.9% | ||
| Q2 25 | — | 49.7% | ||
| Q1 25 | — | 44.4% | ||
| Q4 24 | — | 40.4% | ||
| Q3 24 | — | 43.1% | ||
| Q2 24 | — | 48.4% | ||
| Q1 24 | — | 41.5% |
| Q4 25 | — | 19.4% | ||
| Q3 25 | -100.7% | 15.0% | ||
| Q2 25 | -29.4% | 21.1% | ||
| Q1 25 | 4.7% | 19.8% | ||
| Q4 24 | -14.2% | 18.6% | ||
| Q3 24 | 2.1% | 19.3% | ||
| Q2 24 | -18.4% | 27.4% | ||
| Q1 24 | -247.3% | 18.2% |
| Q4 25 | — | 10.1% | ||
| Q3 25 | -104.7% | 5.9% | ||
| Q2 25 | -41.6% | 10.9% | ||
| Q1 25 | -1.8% | 10.7% | ||
| Q4 24 | -25.2% | 11.2% | ||
| Q3 24 | -2.7% | 10.7% | ||
| Q2 24 | -23.2% | 16.4% | ||
| Q1 24 | -239.9% | 8.1% |
| Q4 25 | — | $1.12 | ||
| Q3 25 | $-10.78 | $0.53 | ||
| Q2 25 | $-3.77 | $1.12 | ||
| Q1 25 | $-0.19 | $1.00 | ||
| Q4 24 | $-2.54 | $1.12 | ||
| Q3 24 | $-0.30 | $0.94 | ||
| Q2 24 | $-2.20 | $1.65 | ||
| Q1 24 | $-25.50 | $0.67 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | ||
|---|---|---|
| 现金及短期投资手头流动性 | $98.1M | $471.4M |
| 总债务越低越好 | $2.5B | — |
| 股东权益账面价值 | $2.0B | $750.2M |
| 总资产 | $5.7B | $6.2B |
| 负债/权益比越低杠杆越低 | 1.23× | — |
8季度趋势,按日历期对齐
| Q4 25 | — | $471.4M | ||
| Q3 25 | $98.1M | $483.3M | ||
| Q2 25 | $151.7M | $420.6M | ||
| Q1 25 | $127.1M | $413.9M | ||
| Q4 24 | $98.3M | $477.7M | ||
| Q3 24 | $143.7M | $534.9M | ||
| Q2 24 | $107.0M | $498.4M | ||
| Q1 24 | $78.5M | $465.3M |
| Q4 25 | — | — | ||
| Q3 25 | $2.5B | — | ||
| Q2 25 | $2.1B | — | ||
| Q1 25 | $2.1B | — | ||
| Q4 24 | $2.1B | — | ||
| Q3 24 | $2.2B | — | ||
| Q2 24 | $2.2B | — | ||
| Q1 24 | $2.2B | — |
| Q4 25 | — | $750.2M | ||
| Q3 25 | $2.0B | $758.5M | ||
| Q2 25 | $2.8B | $800.4M | ||
| Q1 25 | $3.0B | $531.5M | ||
| Q4 24 | $3.0B | $549.0M | ||
| Q3 24 | $3.2B | $551.9M | ||
| Q2 24 | $3.2B | $562.6M | ||
| Q1 24 | $3.3B | $529.9M |
| Q4 25 | — | $6.2B | ||
| Q3 25 | $5.7B | $6.2B | ||
| Q2 25 | $6.4B | $6.1B | ||
| Q1 25 | $6.5B | $5.2B | ||
| Q4 24 | $6.4B | $5.2B | ||
| Q3 24 | $6.8B | $5.2B | ||
| Q2 24 | $6.7B | $5.1B | ||
| Q1 24 | $6.7B | $5.1B |
| Q4 25 | — | — | ||
| Q3 25 | 1.23× | — | ||
| Q2 25 | 0.74× | — | ||
| Q1 25 | 0.70× | — | ||
| Q4 24 | 0.72× | — | ||
| Q3 24 | 0.68× | — | ||
| Q2 24 | 0.70× | — | ||
| Q1 24 | 0.68× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | ||
|---|---|---|
| 经营现金流最新季度 | $-45.5M | $164.7M |
| 自由现金流经营现金流 - 资本支出 | $-94.7M | $58.5M |
| 自由现金流率自由现金流/营收 | -13.5% | 7.9% |
| 资本支出强度资本支出/营收 | 7.0% | 14.4% |
| 现金转化率经营现金流/净利润 | — | 2.21× |
| 过去12个月自由现金流最近4个季度 | $-153.1M | $232.4M |
8季度趋势,按日历期对齐
| Q4 25 | — | $164.7M | ||
| Q3 25 | $-45.5M | $205.2M | ||
| Q2 25 | $-46.8M | $122.5M | ||
| Q1 25 | $65.6M | $98.2M | ||
| Q4 24 | $63.7M | $166.6M | ||
| Q3 24 | $117.9M | $218.1M | ||
| Q2 24 | $-97.9M | $184.3M | ||
| Q1 24 | $-700.0K | $7.5M |
| Q4 25 | — | $58.5M | ||
| Q3 25 | $-94.7M | $135.4M | ||
| Q2 25 | $-84.3M | $53.0M | ||
| Q1 25 | $9.4M | $-14.5M | ||
| Q4 24 | $16.5M | $76.0M | ||
| Q3 24 | $71.4M | $85.7M | ||
| Q2 24 | $-133.2M | $78.8M | ||
| Q1 24 | $-66.8M | $-72.0M |
| Q4 25 | — | 7.9% | ||
| Q3 25 | -13.5% | 22.9% | ||
| Q2 25 | -13.7% | 8.0% | ||
| Q1 25 | 1.4% | -2.5% | ||
| Q4 24 | 2.3% | 11.7% | ||
| Q3 24 | 9.8% | 15.6% | ||
| Q2 24 | -20.9% | 12.9% | ||
| Q1 24 | -9.4% | -13.6% |
| Q4 25 | — | 14.4% | ||
| Q3 25 | 7.0% | 11.8% | ||
| Q2 25 | 6.1% | 10.5% | ||
| Q1 25 | 8.1% | 19.2% | ||
| Q4 24 | 6.7% | 14.0% | ||
| Q3 24 | 6.4% | 24.1% | ||
| Q2 24 | 5.5% | 17.2% | ||
| Q1 24 | 9.3% | 15.0% |
| Q4 25 | — | 2.21× | ||
| Q3 25 | — | 5.88× | ||
| Q2 25 | — | 1.71× | ||
| Q1 25 | — | 1.56× | ||
| Q4 24 | — | 2.30× | ||
| Q3 24 | — | 3.70× | ||
| Q2 24 | — | 1.83× | ||
| Q1 24 | — | 0.17× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
QDEL
| Labs | $373.8M | 53% |
| Point Of Care | $164.6M | 24% |
| Immunohematology | $142.0M | 20% |
| Donor Screening | $14.7M | 2% |
| Molecular Diagnostics | $4.8M | 1% |
| Collaborative Arrangement Transaction With Party To Collaborative Arrangement | $2.1M | 0% |
RHP
| Hotel Other | $157.7M | 21% |
| Gaylord Opryland | $147.4M | 20% |
| Hotel Transient Rooms | $93.6M | 13% |
| Hotel Food And Beverage Outlets | $92.2M | 12% |
| Gaylord Palms | $88.2M | 12% |
| Jw Marriott Hill Country | $53.7M | 7% |
| Entertainment Admissions And Ticketing | $43.1M | 6% |
| Entertainment Food And Beverage | $38.1M | 5% |
| Entertainment Retail And Other | $28.3M | 4% |
| Ac Hotel | $2.4M | 0% |